Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive SBRT with Durvalumab, Platinum, and Etoposide in ES-SCLC
NCT05403723Phase 1Suspended
- Sponsor
- University of Maryland, Baltimore
- Start
- Jan 2027
- Primary completion
- Feb 2028
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of durvalumab in small cell lung cancer (SCLC), sponsored by University of Maryland, Baltimore. Primary endpoint: Incidence of treatment-related adverse events at 2.5 years. Planned start Jan 2027; status: suspended.
02
Drugs
durvalumab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT05403723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05403723.